Xencor, Inc. (XNCR) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -73.2%, revenue growth 13.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $125.58M |
| Revenue (TTM) | $0.1B |
| Net Margin | -73.2% |
| Operating Margin (TTM) | -217.9% |
| Net Debt / EBITDA | -0.5 |
| Revenue Growth (YoY) | 13.7% |
| EPS Growth (YoY) | -65.4% |
| FCF Growth (YoY) | -33.6% |
| Price / Book | 4.00 |
| Price / Sales | 20.24 |
| FCF Yield | -11.0% |
| Altman Z-Score | 3.99 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
XNCR overview · XNCR earnings · XNCR KPIs · XNCR documents · XNCR ownership · XNCR peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.